Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1.7881 in Adult Eosinophilic Esophagitis
2023-508949-40-00Phase 2Authorised
- Sponsor
- Bioprojet
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing BP1.7881A with Matching placebo (2 arms). Primary endpoint: Histologic remission at week 12. Planned start Nov 2024; status: authorised.
02
Drugs
BP1.7881
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2023-508949-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508949-40-00.